Home / 2019 / June / 04

Daily Archives: June 4, 2019

World’s top miners keep performing but investors unimpressed

  • Revenue up 8% to $683 billion
  • EBITDA up 4% to $165 billion
  • Record dividend paid to shareholders of $43 billion, up 13%
  • Market capitalisation of the Top 40 down 18% to $757 billion, 31 Dec 2018 with partial recovery to $849 bn at 30 Apr 2019

LONDON, June 04, 2019 (GLOBE NEWSWIRE) — The world’s 40 largest mining companies continued to consolidate their stellar performance of the past several years by delivering steady growth in 2018, according to PwC’s Mine 2019 report released today.

As a group, the Top 40 increased revenue by 8%, buoyed by higher commodity price rises, and lifted production by 2%. They also boosted cash flows, paid down debt and provided a record dividend to shareholders of $43 billion.  Forecasts indicate continued steady performance in 2019. Revenue should remain stable, with weaker prices for coal and copper offsetting marginally higher production and higher average prices for iron ore.

Yet investors seemed unimpressed by the Top 40’s result, judging by market valuations, which fell 18% over 2018. While total market capitalization rose in the first term of this year, it remains 8% down compared to the end of 2017.  Over the past 15 years, total shareholders’ return in mining has lagged that of the market as a whole as well as comparable industries such as oil and gas.

PwC’s Global Mining and Metals leader, Jock O’Callaghan, said: “One thing is clear – mining requires more than good financial performance to continue to create and realise value in a sustainable manner.

“We believe that the market has reservations about the mining industry’s ability to respond to the risks and uncertainties of a changing world.

“With strong balance sheets and cash flows, now is the time for the Top 40 to address the issues weighing down market values: climate change, shifting consumer sentiment, and technology adoption.

“Miners need to move swiftly to restore faith in ‘brand mining. As an industry, this means transforming their reputation as efficient ‘converters of dirt’ posing omnipresent environmental risk to prominent builders of both economic and societal capital. Prioritising greener and consumer-centric strategies, enabled by technology, will help earn the trust of stakeholders and enable miners to create sustainable value into the future.”

Balance sheets remain strong; capital expenditure up but slow

In 2018 the Top 40 paid down $15.5 billion in net borrowings, resulting in the gearing position dropping below the 10-year average. All liquidity and solvency ratios improved during the year, leaving the world’s largest miners with strong balance sheets and cash flows.

In line with expectations, capital expenditures started to rise again, albeit from historically low levels.  The 13% increase over the previous year to $57 billion suggests that miners are continuing to proceed cautiously; approximately half (48%) of the capital expenditure in 2018 was for ongoing projects.

Copper and gold dominated spending in 2018, attracting $30 billion worth of investment. Capital expenditure on coal was consistent, year on year, and it is expected that miners will maintain current production levels while the coal price remains high.

Shareholders, government and other stakeholders rewarded

An 11% lift in operating cash flows has allowed the Top 40 to increase shareholder distributions in 2018 to a record $43 billion. Dividend yield for the year was 5.5%. There was a notable jump in share buybacks to $15 billion, up from $4 billion in 2017. Rio Tinto and BHP accounted for 70% of the total activity returning proceeds of non-core disposals to shareholders.

“While their shareholders see buybacks as welcome news in the short term, miners need to ask whether this has come at a cost given the challenges of attracting long-term capital.” said Mr O’Callaghan.  “Equity raisings during the year remained at a paltry $3bn, lower than the preceding two years.”

In 2018 the share of value distributed to governments in the form of direct taxes and royalties increased from 19% to 21%. Employees received 22% of the total value distribution from the Top 40.

M&A activity picks up

After several years of sluggish activity, M&A picked up significantly in 2018. The value of announced transactions rose 137% to $30 billion, driven by a flurry of activity in the gold sector, the on-going push by miners to optimise their portfolios, and momentum to acquire energy metals projects.

“The renewed appetite for large transactions looks set to continue this year, with announced deal value to 30 April already exceeding the whole of 2017,” said Mr O’Callaghan. “Post merger disposal of non-core assets in revised portfolios will support more deals activity in the near term.”

Gold sector consolidating

The gold sector is experiencing a renewed round of consolidation, driven by a shrinking pipeline of projects, fewer new high-grade discoveries and a lack of funding for junior developments. Gold deals increased from 8% of total Top 40 deal value in 2017 to 25% in 2018, and this year are tracking at close to 95% of deals as at the end of April.

“In the current market, gold mining companies need to be rigorous and disciplined with prospective deals. Investors are still reeling from the spate of overpriced deals between 2005 to 2012, the value of which has now been lost,” Mr O’Callaghan said.

Notes to editors:

PwC’s Mine 2019 analysis is based on the major top 40 global mining companies by market capitalization. The results aggregated in this report have been sourced from the latest publicly available information, primarily annual reports and financial reports available to shareholders. The full report can be accessed via the following link: www.pwc.com/mine

About PwC

At PwC, our purpose is to build trust in society and solve important problems. We’re a network of firms in 157 countries with more than 223,000 people who are committed to delivering quality in assurance, advisory and tax services. Find out more and tell us what matters to you by visiting us at www.pwc.com.

PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details.

© 2019 PwC. All rights reserved

Contact David Bowden
Global Communications Manager | PwC
m: +44 (0)7483365049
e: david.bowden@pwc.com

 

Vielight Commences Pivotal Clinical Trial for Alzheimer’s Disease based on Transcranial Photobiomodulation.

Toronto, Canada, June 04, 2019 (GLOBE NEWSWIRE) –Vielight Inc. of Toronto, a leader in brain photobiomodulation (PBM) technology, announces that the primary site for its pivotal clinical trial, St. Michael’s Hospital, in Toronto, has been activated. The trial will be a randomized, placebo-controlled study involving 228 subjects with moderate to severe cognitive impairment due to Alzheimer’s Disease.

This pivotal trial will be conducted across North America. St. Michael’s Hospital is the first among the eight sites that will carry out the study. The protocol of the study has been reviewed by the U.S. Food and Drug Administration (FDA) and Health Canada.

The device in investigation, called the “Vielight Neuro RX Gamma”, is based on Vielight’s proprietary PBM technology which directs near infrared light, pulsing at the gamma rate of 40 Hz, to selected regions of the brain. The procedure is non-invasive, and the device has been designed to be suitable for home-use. Subject to regulatory clearance, the device will be indicated for Alzheimer patients with moderate to severe impairment, the group that demands the most care and has the largest economic burden.

This clinical trial is timely against the backdrop of many unsuccessful attempts by pharmaceutical and device companies to demonstrate acceptable efficacy and safety to address the disease. Currently, no other modality is in a clinical trial that is expected to demonstrate clinical outcomes within the time anticipated for the Vielight study to be completed.

Recently published studies have shed more light on the potential of the Neuro RX Gamma to modify the pathology of Alzheimer’s Disease. These studies presented findings in clinical assessments and functional magnetic resonance imaging (fMRI), warranting the move forward with the large pivotal clinical trial.

Recruitment for the study will begin shortly. The trial will be independently managed by the Applied Health Research Centre (AHRC), a methodology center affiliated with St. Michael’s Hospital. Further information and contact details for participation enquiries can be found at https://clinicaltrials.gov/ct2/show/NCT03484143.

Principal Investigator at St. Michael’s Hospital, Dr. Corinne Fischer, M.D., said, “In spite of substantial efforts to establish effective treatments for Alzheimer’s disease, progress has been, unfortunately, limited and a cure does not yet exist. Although not conventional as an Alzheimer’s disease solution, we look forward to investigating the potential of Vielight’s technology in the treatment of this difficult disease based on promising early evidence.”

Margaret A. Naeser, Ph.D., Research Professor of Neurology, Boston University School of Medicinesaid: “My research studies into the use of PBM in aphasia, post-traumatic stress disorder (PTSD), traumatic brain injury, and dementia have shown me that we are seeing just the tip of the iceberg of healing potential for this technology.”

Michael Hamblin Ph.D., Retired Principal Investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital, and Associate Professor of Dermatology at Harvard Medical School, said, “For more than 50 years, researchers have been demonstrating the potential of PBM to treat many medical conditions. However, large controlled clinical trials have been elusive. Vielight has been the first to demonstrate successful clinical outcomes for dementia in small early investigations, and we look forward to the findings of this pivotal trial.”

Lew Lim, Ph.D., Founder and CEO of Vielight, expressed, “A very complex disease like Alzheimer’s poses a big challenge to any researcher, and even more so for a small team like ours. Despite the solid science and strong early evidence, few were ready to ride with us. I am grateful to the courageous parties who have helped us to get to this point of a major clinical trial. I hope that we will all be a part of something special and important in the end.”

About Vielight Inc.Vielight Inc. is a recognized leader in the application of photobiomodulation (PBM) for supporting mental and physical well-being. Much of Vielight’s work has been focused on research of the effects of PBM on the brain, and on translation of PBM technology into practical uses. For more info visit company’s website: https://vielight.com.

Attachment

Gennady Lemud
Vielight Inc.
1-877-355-8012
gennady@vielight.com

Cocoon Medical Appoints Miguel Pardos as Chief Executive Officer

Barcelona, Spain, May. 27, 2019 – Cocoon Medical (“Cocoon”), a leading developer and provider of energy-based aesthetic systems for practitioners worldwide, today announced the appointment of Miguel Pardos as its Chief Executive Officer (“CEO”), effective immediately.

Immediately prior to joining Cocoon, Mr. Pardos served as the Vice President Aesthetic APAC at Lumenis based in Hong Kong.  Prior to Lumenis, Mr. Pardos was the Executive Vice President International of Cutera Inc. from July 2014 until February 2018.  From 2009-2014, he was the Vice President Asia Pacific at Syneron Candela. At Syneron Candela, Mr. Pardos implemented commercial strategies for direct and distribution channel while integrating Candela into Syneron product portfolio. Prior to Syneron Candela Mr. Pardos held a variety of global management positions of increasing responsibility within GE Healthcare from 1999-2007, during his time at GE Healthcare Mr Pardos has held management positions in Spain, Germany, Australia and Singapore.

“We’re delighted to welcome Miguel to Cocoon, and are pleased to have been able to attract a seasoned aesthetic medical device industry executive of his caliber to lead Cocoon into its next phase of growth and international expansion,” said José Antonio Sánchez, Chairman and Founder of Cocoon Group. “ Mr. Pardos brings to Cocoon 20 years of executive leadership where 10 years were of direct experience in the Aesthetic industry with an strong international background, which I believe will contribute greatly to Cocoon’s new phase of growth and development”.

Mr. Pardos said, “I am honored to be joining Cocoon at this very important moment of growth and international expansion with a healthy product pipeline. Cocoon is a successful and innovative company well positioned to expand its footprint internationally by delivering the best products in the market under the brands Cooltech and Primelase in the categories of body shaping and laser hair removal respectively.  As part of the team I look forward to leading the organization to gain global market share through commercial execution and international expansion.”

Mr. Pardos holds a BS Engineering by UPC Barcelona and Master Engineering by University Europea Madrid. Mr. Pardos also holds an International EMBA by Instituto de Empresa (Ie).

About Cocoon Medical

Cocoon Medical is an international company headquartered in Barcelona. The company’s aim is to offer the highest technology and innovation at the aesthetic medicine field, developing medical and aesthetic equipment in order to satisfy the needs of the most demanding customers.
The continuous effort of each employee of cocoon medical has managed to consolidate its global positioning. Cocoon has developed a wide international penetration supported by more than 66 renowned distributors, in which Cocoon relies to meet the specific needs of each market  offering the most appropriate customized solutions to give the best service to customers.

Cocoon Medical  is characterized by its important and continuous investment in the development of superior innovations and quality by its own R & D department and factories,  the highest quality certifications, and the best service in the sector.

Cocoon Medical Appoints Miguel Pardos as Chief Executive Officer

Barcelona, Spain, May. 27, 2019 – Cocoon Medical (“Cocoon”), a leading developer and provider of energy-based aesthetic systems for practitioners worldwide, today announced the appointment of Miguel Pardos as its Chief Executive Officer (“CEO”), effective immediately.

Immediately prior to joining Cocoon, Mr. Pardos served as the Vice President Aesthetic APAC at Lumenis based in Hong Kong.  Prior to Lumenis, Mr. Pardos was the Executive Vice President International of Cutera Inc. from July 2014 until February 2018.  From 2009-2014, he was the Vice President Asia Pacific at Syneron Candela. At Syneron Candela, Mr. Pardos implemented commercial strategies for direct and distribution channel while integrating Candela into Syneron product portfolio. Prior to Syneron Candela Mr. Pardos held a variety of global management positions of increasing responsibility within GE Healthcare from 1999-2007, during his time at GE Healthcare Mr Pardos has held management positions in Spain, Germany, Australia and Singapore.

“We’re delighted to welcome Miguel to Cocoon, and are pleased to have been able to attract a seasoned aesthetic medical device industry executive of his caliber to lead Cocoon into its next phase of growth and international expansion,” said José Antonio Sánchez, Chairman and Founder of Cocoon Group. “ Mr. Pardos brings to Cocoon 20 years of executive leadership where 10 years were of direct experience in the Aesthetic industry with an strong international background, which I believe will contribute greatly to Cocoon’s new phase of growth and development”.

Mr. Pardos said, “I am honored to be joining Cocoon at this very important moment of growth and international expansion with a healthy product pipeline. Cocoon is a successful and innovative company well positioned to expand its footprint internationally by delivering the best products in the market under the brands Cooltech and Primelase in the categories of body shaping and laser hair removal respectively.  As part of the team I look forward to leading the organization to gain global market share through commercial execution and international expansion.”

Mr. Pardos holds a BS Engineering by UPC Barcelona and Master Engineering by University Europea Madrid. Mr. Pardos also holds an International EMBA by Instituto de Empresa (Ie).

About Cocoon Medical

Cocoon Medical is an international company headquartered in Barcelona. The company’s aim is to offer the highest technology and innovation at the aesthetic medicine field, developing medical and aesthetic equipment in order to satisfy the needs of the most demanding customers.
The continuous effort of each employee of cocoon medical has managed to consolidate its global positioning. Cocoon has developed a wide international penetration supported by more than 66 renowned distributors, in which Cocoon relies to meet the specific needs of each market  offering the most appropriate customized solutions to give the best service to customers.

Cocoon Medical  is characterized by its important and continuous investment in the development of superior innovations and quality by its own R & D department and factories,  the highest quality certifications, and the best service in the sector.

Cocoon Medical Appoints Miguel Pardos as Chief Executive Officer

Barcelona, Spain, May. 27, 2019 – Cocoon Medical (“Cocoon”), a leading developer and provider of energy-based aesthetic systems for practitioners worldwide, today announced the appointment of Miguel Pardos as its Chief Executive Officer (“CEO”), effective immediately.

Immediately prior to joining Cocoon, Mr. Pardos served as the Vice President Aesthetic APAC at Lumenis based in Hong Kong.  Prior to Lumenis, Mr. Pardos was the Executive Vice President International of Cutera Inc. from July 2014 until February 2018.  From 2009-2014, he was the Vice President Asia Pacific at Syneron Candela. At Syneron Candela, Mr. Pardos implemented commercial strategies for direct and distribution channel while integrating Candela into Syneron product portfolio. Prior to Syneron Candela Mr. Pardos held a variety of global management positions of increasing responsibility within GE Healthcare from 1999-2007, during his time at GE Healthcare Mr Pardos has held management positions in Spain, Germany, Australia and Singapore.

“We’re delighted to welcome Miguel to Cocoon, and are pleased to have been able to attract a seasoned aesthetic medical device industry executive of his caliber to lead Cocoon into its next phase of growth and international expansion,” said José Antonio Sánchez, Chairman and Founder of Cocoon Group. “ Mr. Pardos brings to Cocoon 20 years of executive leadership where 10 years were of direct experience in the Aesthetic industry with an strong international background, which I believe will contribute greatly to Cocoon’s new phase of growth and development”.

Mr. Pardos said, “I am honored to be joining Cocoon at this very important moment of growth and international expansion with a healthy product pipeline. Cocoon is a successful and innovative company well positioned to expand its footprint internationally by delivering the best products in the market under the brands Cooltech and Primelase in the categories of body shaping and laser hair removal respectively.  As part of the team I look forward to leading the organization to gain global market share through commercial execution and international expansion.”

Mr. Pardos holds a BS Engineering by UPC Barcelona and Master Engineering by University Europea Madrid. Mr. Pardos also holds an International EMBA by Instituto de Empresa (Ie).

About Cocoon Medical

Cocoon Medical is an international company headquartered in Barcelona. The company’s aim is to offer the highest technology and innovation at the aesthetic medicine field, developing medical and aesthetic equipment in order to satisfy the needs of the most demanding customers.
The continuous effort of each employee of cocoon medical has managed to consolidate its global positioning. Cocoon has developed a wide international penetration supported by more than 66 renowned distributors, in which Cocoon relies to meet the specific needs of each market  offering the most appropriate customized solutions to give the best service to customers.

Cocoon Medical  is characterized by its important and continuous investment in the development of superior innovations and quality by its own R & D department and factories,  the highest quality certifications, and the best service in the sector.

NANOBIOTIX APPOINTS NEW CHIEF MEDICAL OFFICER AS THE COMPANY EVOLVES AFTER ACHIEVEMENT OF EUROPEAN MARKET APPROVAL

NANOBIOTIX APPOINTS NEW CHIEF MEDICAL OFFICER AS THE COMPANY EVOLVES AFTER ACHIEVEMENT OF EUROPEAN MARKET APPROVAL

  • Biopharmaceutical veteran Edwina Baskin-Bey, M.D., joins Nanobiotix as its new Chief Medical Officer (CMO)
  • Dr. Baskin-Bey will leverage her expertise in medical strategy and late-stage clinical development to help accelerate the company’s strategic objectives
  • Dr. Baskin-Bey succeeds Elsa Borghi, M.D., who will remain focused on the early development of innovative products at Nanobiotix

“Dr. Baskin-Bey has built an impressive career and she is joining us at a critical time. As we advance development of NBTXR3 in multiple solid tumor indications and in combination with checkpoint inhibitors, Dr. Baskin-Bey’s breadth and depth of experience align perfectly with our strategic leadership needs. To date, Dr. Borghi has been instrumental in bringing our lead product to European market approval. I am excited that she will continue to create and develop new innovative approaches for Nanobiotix.” – Laurent Levy, CEO of Nanobiotix

“It is an honor and a privilege to join Nanobiotix. I am thrilled by the opportunity to lead a dedicated team that operates on the cutting edge of nanophysics to develop unique treatment solutions and improve patient outcomes. My experience in global oncology product development, surgery and radiation should serve to help us grow and to accelerate our global clinical programs.” – Dr. Edwina Baskin-Bey, CMO of Nanobiotix

Paris, France and Cambridge, Massachusetts, USA, June 4, 2019 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it has appointed Edwina Baskin-Bey, M.D. as its new CMO.

Dr. Baskin-Bey brings over 18 years of oncology clinical development and basic science experience in academia and industry, most recently serving as CMO of North Carolina-based oncology start-up, Innocrin Pharmaceuticals. As a member of the Executive Team at Innocrin, Dr. Baskin-Bey led development and implementation of the overall clinical and corporate strategy from phase I to phase III. She was responsible for the Medical, Regulatory, Pharmacovigilance, Clinical Operations, Biostatistics, and Data Management functions.

Dr. Baskin-Bey joined Innocrin from Janssen Oncology of Johnson & Johnson, where she was charged with leading both early- and late-stage oncology global development programs for in-licensed products from Aragon and Tesaro, apalutamide and niraparib. Previously, she worked for more than six years at Astellas Pharma. At Astellas, BV, Netherlands Headquarters, Dr. Baskin-Bey, was responsible for several early-stage oncology programs, most notably, she co-led with the alliance partner, Medivation, the global development strategy for the in-licensed product enzalutamide, leading to FDA approval, EMA approval, and label expansions. Also while at Astellas, she served at the UK Headquarters as head of European Medical Affairs, where she was responsible for the launch of enzalutamide in Europe.

Dr. Baskin-Bey currently serves as an independent board member for Catalyst Clinical Research, LLC, in North Carolina. Dr. Baskin-Bey obtained her bachelor’s degree from Hunter College in New York, and earned her medical degree at Mount Sinai/New York University (NYU) School of Medicine. She trained in general surgery and oncology for seven years at The Mayo Clinic in Rochester, MN, and in basic science research principles at the National Institute of Health (NIH).

Dr. Baskin-Bey succeeds accomplished Nanobiotix CMO, Elsa Borghi, M.D. Dr. Borghi will remain with the company in a key leadership role focused on early development and innovation.

About NANOBIOTIX: www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotix’s first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany.

Contact

Nanobiotix
Communications Department
+33 (0)1 40 26 07 55
+1 (617) 852-4835
contact@nanobiotix.com
 

Investor Relations Department
+33 (0)1 79 97 29 99
+1 (646) 241-4400
investors@nanobiotix.com

Media relations
France – Springbok Consultants
Marina Rosoff
+33 (0)6 71 58 00 34
marina@springbok.fr
United States – RooneyPartners
Marion Janic
+1 (212) 223-4017
mjanic@rooneyco.com

 

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered with the French Financial Markets Authority (Autorité des Marchés Financiers) under number R.19-018 on April 30, 2019 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

Attachment

NANOBIOTIX APPOINTS NEW CHIEF MEDICAL OFFICER AS THE COMPANY EVOLVES AFTER ACHIEVEMENT OF EUROPEAN MARKET APPROVAL

NANOBIOTIX APPOINTS NEW CHIEF MEDICAL OFFICER AS THE COMPANY EVOLVES AFTER ACHIEVEMENT OF EUROPEAN MARKET APPROVAL

  • Biopharmaceutical veteran Edwina Baskin-Bey, M.D., joins Nanobiotix as its new Chief Medical Officer (CMO)
  • Dr. Baskin-Bey will leverage her expertise in medical strategy and late-stage clinical development to help accelerate the company’s strategic objectives
  • Dr. Baskin-Bey succeeds Elsa Borghi, M.D., who will remain focused on the early development of innovative products at Nanobiotix

“Dr. Baskin-Bey has built an impressive career and she is joining us at a critical time. As we advance development of NBTXR3 in multiple solid tumor indications and in combination with checkpoint inhibitors, Dr. Baskin-Bey’s breadth and depth of experience align perfectly with our strategic leadership needs. To date, Dr. Borghi has been instrumental in bringing our lead product to European market approval. I am excited that she will continue to create and develop new innovative approaches for Nanobiotix.” – Laurent Levy, CEO of Nanobiotix

“It is an honor and a privilege to join Nanobiotix. I am thrilled by the opportunity to lead a dedicated team that operates on the cutting edge of nanophysics to develop unique treatment solutions and improve patient outcomes. My experience in global oncology product development, surgery and radiation should serve to help us grow and to accelerate our global clinical programs.” – Dr. Edwina Baskin-Bey, CMO of Nanobiotix

Paris, France and Cambridge, Massachusetts, USA, June 4, 2019 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it has appointed Edwina Baskin-Bey, M.D. as its new CMO.

Dr. Baskin-Bey brings over 18 years of oncology clinical development and basic science experience in academia and industry, most recently serving as CMO of North Carolina-based oncology start-up, Innocrin Pharmaceuticals. As a member of the Executive Team at Innocrin, Dr. Baskin-Bey led development and implementation of the overall clinical and corporate strategy from phase I to phase III. She was responsible for the Medical, Regulatory, Pharmacovigilance, Clinical Operations, Biostatistics, and Data Management functions.

Dr. Baskin-Bey joined Innocrin from Janssen Oncology of Johnson & Johnson, where she was charged with leading both early- and late-stage oncology global development programs for in-licensed products from Aragon and Tesaro, apalutamide and niraparib. Previously, she worked for more than six years at Astellas Pharma. At Astellas, BV, Netherlands Headquarters, Dr. Baskin-Bey, was responsible for several early-stage oncology programs, most notably, she co-led with the alliance partner, Medivation, the global development strategy for the in-licensed product enzalutamide, leading to FDA approval, EMA approval, and label expansions. Also while at Astellas, she served at the UK Headquarters as head of European Medical Affairs, where she was responsible for the launch of enzalutamide in Europe.

Dr. Baskin-Bey currently serves as an independent board member for Catalyst Clinical Research, LLC, in North Carolina. Dr. Baskin-Bey obtained her bachelor’s degree from Hunter College in New York, and earned her medical degree at Mount Sinai/New York University (NYU) School of Medicine. She trained in general surgery and oncology for seven years at The Mayo Clinic in Rochester, MN, and in basic science research principles at the National Institute of Health (NIH).

Dr. Baskin-Bey succeeds accomplished Nanobiotix CMO, Elsa Borghi, M.D. Dr. Borghi will remain with the company in a key leadership role focused on early development and innovation.

About NANOBIOTIX: www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotix’s first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany.

Contact

Nanobiotix
Communications Department
+33 (0)1 40 26 07 55
+1 (617) 852-4835
contact@nanobiotix.com
 

Investor Relations Department
+33 (0)1 79 97 29 99
+1 (646) 241-4400
investors@nanobiotix.com

Media relations
France – Springbok Consultants
Marina Rosoff
+33 (0)6 71 58 00 34
marina@springbok.fr
United States – RooneyPartners
Marion Janic
+1 (212) 223-4017
mjanic@rooneyco.com

 

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered with the French Financial Markets Authority (Autorité des Marchés Financiers) under number R.19-018 on April 30, 2019 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

Attachment